
zzso an zzso drug which interacts with both zzso zzso I and II, has demonstrated a broad spectrum of activity in zzso zzso This indicates further clinical zzso In the present phase I study, with the primary objective to determine the maximum tolerated dose, zzso was administered by a 24 h continuous infusion every 21 days to 32 patients with solid zzso zzso The patients received zzso zzso by a central zzso zzso Liver toxicity was dose zzso One patient died in a zzso coma after the first course zzso 640 zzso which was associated with zzso zzso Other side effects were sporadic and zzso zzso was virtually zzso Twenty-two patients had stable disease for four to six courses of zzso The plasma zzso zzso were compatible with standard linear zzso models, with a protracted terminal zzso zzso 115 zzso Although one sudden death occurred probably due to zzso zzso we nevertheless feel that research with zzso should continue, mainly because of its zzso activity and its unique mechanism of zzso The recommended dose for phase II studies with zzso administered as a 24 h infusion is zzso zzso Liver zzso also seen in studies employing other zzso and infusion zzso should be investigated extensively in further clinical zzso 

